Skip to content Skip to footer

Company

Oxurion is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of vision loss in elderly people worldwide.

Our ambition is to crack the code of GA

While a lot of companies focused their research based on the genetic origins of AMD (e.g. complement pathway), we decided to tackle the disease from a different angle, focusing mainly on the identification of cytoprotective targets through CRISPR-based target discovery platform.

Our Mission

Our Mission

To prevent blindness by pioneering life changing treatments that address unmet medical needs in ophthalmology, with a focus on retinal diseases including Age-related Macular Degeneration (AMD).

Oxurion is headquartered in Leuven, Belgium, and is listed on Euronext Brussels under the symbol OXUR

Your Vision is Our Vision

We are united by the shared goal of helping people to see better.

We are collaborative, resilient, and turn challenges into opportunities.

Team

Executive Team

Pascal Ghoson

CEO/CFO

Andy De Deene, MD, MBA

Chief Development Officer

Philippe Barbeaux

Chief Scientific Officer

Team

BOARD OF DIRECTORS

Charles Paris de Bollardière

Chairman Of The Board

James Hartmann

Independent Non-Executive Director

Pascal Ghoson

CEO/CFO

Nathalie Laarakker, CPA

Non-Executive, Independent Director

Dr. Anat Loewenstein, MD, MHA

Non-Executive, Independent Director

Let's Talk

To inquire regarding partnership opportunities with Oxurion, please contact:

Chief Executive Officer